BioAge Labs Investors Can Lead Class Action Lawsuit After Major Losses
SAN DIEGO, March 6, 2025 /PRNewswire/ -- Robbins Geller Rudman & Dowd LLP, a prominent law firm, has announced urgent news for investors affected by substantial losses in BioAge Labs, Inc. This opportunity is available for those who purchased shares during the company's initial public offering (IPO) held on September 26, 2024. Investors have until March 10, 2025, to step up and act as lead plaintiffs in a class action lawsuit against BioAge Labs and some of their top executives, following allegations of violations of the Securities Act of 1933.
In the IPO, BioAge Labs issued a total of 12.65 million shares at an initial price of $18.00 each. However, the excitement surrounding the IPO was quickly overshadowed by alarming developments. The lawsuit, officially referred to as Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), accuses the company of misleading investors regarding the safety of its products, particularly concerning its clinical trial known as STRIDES.
The core allegation is that BioAge Labs promoted its therapies without disclosing known safety concerns, ultimately causing investor devastation when results from the STRIDES trial fell short. On December 6, 2024, it was publicly announced that the ongoing Phase 2 study would be halted due to liver-related side effects observed in trial participants using its investigational drug, azelaprag. Subsequently, this news led to an astounding drop in BioAge Labs’ stock price, which plummeted more than 76% and has since hovered around $5.82 per share.
The Private Securities Litigation Reform Act of 1995 allows any investor who bought BioAge Labs stock through the IPO registration statement to pursue the lead plaintiff position in the class action lawsuit. The criteria are straightforward: the lead plaintiff must exhibit the largest financial interest correlated with the class's claims and be representative of the class’s interests. This individual will have the authority to choose a law firm to spearhead the litigation aimed at recovering damages for affected investors.
Recognized as one of the leading legal practices for investors tackling securities fraud, Robbins Geller Rudman & Dowd LLP has built a reputation over the past years for adeptly securing favorable settlements for their clients. They boast a history of recovering $6.6 billion in securities class action cases alone, making them a formidable presence in the legal field. Their track record includes achieving the largest securities class action recovery in history, valued at $7.2 billion in the case involving Enron Corp.
As BioAge Labs investors consider their next moves, it's critical to act swiftly given the impending deadline. Those looking to connect with Robbins Geller’s attorneys, J.C. Sanchez or Jennifer N. Caringal, can reach out via phone at 800-449-4900 or by email at [email protected] This is a crucial moment for investors looking to reclaim their losses following the troubled IPO of BioAge Labs. Please visit the law firm's dedicated BioAge Cases page for more details on how to participate and take action.
In turbulent market conditions such as these, time is of the essence for shareholders aiming to seek justice and accountability from BioAge Labs, ensuring similar transgressions do not go unchecked in the future. Investors must stay informed and make decisive moves to secure their financial interests.
Investor Information
In the IPO, BioAge Labs issued a total of 12.65 million shares at an initial price of $18.00 each. However, the excitement surrounding the IPO was quickly overshadowed by alarming developments. The lawsuit, officially referred to as Soto v. BioAge Labs, Inc., No. 25-cv-00196 (N.D. Cal.), accuses the company of misleading investors regarding the safety of its products, particularly concerning its clinical trial known as STRIDES.
The core allegation is that BioAge Labs promoted its therapies without disclosing known safety concerns, ultimately causing investor devastation when results from the STRIDES trial fell short. On December 6, 2024, it was publicly announced that the ongoing Phase 2 study would be halted due to liver-related side effects observed in trial participants using its investigational drug, azelaprag. Subsequently, this news led to an astounding drop in BioAge Labs’ stock price, which plummeted more than 76% and has since hovered around $5.82 per share.
Legal Implications
The Private Securities Litigation Reform Act of 1995 allows any investor who bought BioAge Labs stock through the IPO registration statement to pursue the lead plaintiff position in the class action lawsuit. The criteria are straightforward: the lead plaintiff must exhibit the largest financial interest correlated with the class's claims and be representative of the class’s interests. This individual will have the authority to choose a law firm to spearhead the litigation aimed at recovering damages for affected investors.
About Robbins Geller Rudman & Dowd LLP
Recognized as one of the leading legal practices for investors tackling securities fraud, Robbins Geller Rudman & Dowd LLP has built a reputation over the past years for adeptly securing favorable settlements for their clients. They boast a history of recovering $6.6 billion in securities class action cases alone, making them a formidable presence in the legal field. Their track record includes achieving the largest securities class action recovery in history, valued at $7.2 billion in the case involving Enron Corp.
As BioAge Labs investors consider their next moves, it's critical to act swiftly given the impending deadline. Those looking to connect with Robbins Geller’s attorneys, J.C. Sanchez or Jennifer N. Caringal, can reach out via phone at 800-449-4900 or by email at [email protected] This is a crucial moment for investors looking to reclaim their losses following the troubled IPO of BioAge Labs. Please visit the law firm's dedicated BioAge Cases page for more details on how to participate and take action.
In turbulent market conditions such as these, time is of the essence for shareholders aiming to seek justice and accountability from BioAge Labs, ensuring similar transgressions do not go unchecked in the future. Investors must stay informed and make decisive moves to secure their financial interests.
Topics Financial Services & Investing）
【About Using Articles】
You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.
【About Links】
Links are free to use.